c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.

PubWeight™: 1.27‹?› | Rank: Top 10%

🔗 View Article (PMID 10544177)

Published in FASEB J on November 01, 1999

Authors

B H Brandt1, A Roetger, T Dittmar, G Nikolai, M Seeling, A Merschjann, J R Nofer, G Dehmer-Möller, R Junker, G Assmann, K S Zaenker

Author Affiliations

1: Institut für Klinische Chemie und Laboratoriumsmedizin, 48149 Münster, Germany Institut für Immunologie, Universität Witten/Herdecke, Witten 58453, Germany. brandt@uni-muenster.de

Articles citing this

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol (2000) 2.18

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell (2004) 1.63

Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol Biol Cell (2005) 1.51

Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. Biophys J (2005) 1.47

Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. Biophys J (2009) 1.33

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell (2004) 1.26

The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell (2005) 1.22

Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. Breast Cancer Res (2010) 1.14

HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J (2003) 1.14

Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08

Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells. Clin Exp Metastasis (2010) 0.99

S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation. PLoS One (2008) 0.97

A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Biophys J (2006) 0.97

Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90

Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk. Cell Commun Signal (2012) 0.87

HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem (2009) 0.85

SMURF1 plays a role in EGF-induced breast cancer cell migration and invasion. Mol Cells (2013) 0.83

Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Br J Cancer (2004) 0.82

Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol Cancer (2014) 0.82

Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol (2014) 0.80

Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells. PLoS One (2012) 0.79

Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg Med Chem Lett (2011) 0.75

Articles by these authors

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 7.04

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60

The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81

Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis (1983) 2.37

The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res (1997) 2.14

xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res (2001) 2.10

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2001) 2.03

Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat (2003) 1.93

KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90

Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res (1993) 1.85

Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol (2001) 1.80

Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood (2001) 1.75

Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem (1990) 1.75

Characterization of an F-actin-binding domain in the cytoskeletal protein vinculin. J Cell Biol (1994) 1.72

A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A (1991) 1.69

Risk factors for inadequate emergence after anesthesia: emergence delirium and hypoactive emergence. Minerva Anestesiol (2010) 1.67

C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J (2000) 1.63

Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function. Genes Dev (1998) 1.58

A novel frameshift mutation in PMP22 accounts for hereditary neuropathy with liability to pressure palsies. Neurology (1997) 1.56

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb (1994) 1.52

Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry (1975) 1.50

Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem (1997) 1.50

Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study. J Hypertens (1998) 1.48

D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J (1999) 1.48

Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J (2002) 1.47

Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion (2010) 1.45

Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem (1983) 1.45

Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood (1999) 1.44

Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost (1998) 1.43

Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem (2001) 1.43

Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation (1997) 1.43

Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci (Lond) (1998) 1.40

[Primary and secondary prevention of coronary heart disease. A position paper of the International Task Force for the Prevention of Coronary Heart Disease]. Dtsch Med Wochenschr (2000) 1.39

Foetal growth restriction in children with prothrombotic risk factors. Thromb Haemost (2001) 1.39

Measurement of prostate-specific antigen: no advantage to ultrasensitive assays? J Natl Cancer Inst (1996) 1.39

Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res (1996) 1.37

Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol (1999) 1.34

Hind III RFLP in the lipoprotein lipase gene, (LPL). Nucleic Acids Res (1987) 1.32

Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol (2000) 1.32

Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem (1990) 1.31

Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27

Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster. J Clin Endocrinol Metab (2000) 1.26

Pst I RFLP close to the LDL receptor gene. Nucleic Acids Res (1986) 1.26

Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25

The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. Atherosclerosis (1977) 1.24

The ERR-1 orphan receptor is a transcriptional activator expressed during bone development. Mol Endocrinol (1997) 1.23

Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPARalpha) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice. J Biol Chem (1999) 1.21

Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood (1999) 1.19

Sterol carrier protein X is peroxisomal 3-oxoacyl coenzyme A thiolase with intrinsic sterol carrier and lipid transfer activity. J Biol Chem (1994) 1.19

Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol (2000) 1.18

Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med (Berl) (2000) 1.18

The LQT syndromes--current status of molecular mechanisms. Z Kardiol (1999) 1.18

Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem (1986) 1.17

Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem (1998) 1.17

Interaction of high density lipoproteins with cholesteryl ester-laden macrophages: biochemical and morphological characterization of cell surface receptor binding, endocytosis and resecretion of high density lipoproteins by macrophages. EMBO J (1985) 1.17

Lipid-protein interactions in high density lipoproteins. Proc Natl Acad Sci U S A (1974) 1.17

A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest (1991) 1.16

Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res (1991) 1.16

Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis (1999) 1.15

Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes (2000) 1.15

Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest (1991) 1.15

Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver. J Biol Chem (1973) 1.14

Isolation and characterization of an abnormal high density lipoprotein in Tangier Diesase. J Clin Invest (1977) 1.13

A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A (1994) 1.13

Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer (1998) 1.12

Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. Int J Obes Relat Metab Disord (2004) 1.12

The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins. J Clin Invest (1977) 1.12

Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res (1999) 1.11

The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem Biophys Res Commun (1994) 1.10

Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J (1999) 1.10

Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol (2000) 1.09

An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest (1996) 1.08

Acceleration of reverse cholesterol transport. Curr Opin Cardiol (2000) 1.08

Serum ferritin, transferrin, haptoglobin, and iron in middle- and long-distance runners, elite rowers, and professional racing cyclists. Int J Sports Med (1981) 1.07

An improved method for quantification of cholesterol and cholesteryl esters in human monocyte-derived macrophages by high performance liquid chromatography with identification of unassigned cholesteryl ester species by means of secondary ion mass spectrometry. J Lipid Res (1997) 1.07

Polymorphisms in the apolipoprotein AI-CIII gene complex. Mol Biol Med (1986) 1.07

Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.06

Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. Stroke (2000) 1.05

Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation (1999) 1.05

Simplified turbidimetric determination of apolipoproteins A-I, A-II and B using a microtitre method. J Clin Chem Clin Biochem (1988) 1.04

Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J Biol Chem (1999) 1.04

The relationship of lipoprotein (a) (Lp(a)) to risk factors of coronary heart disease: initial results of the prospective epidemiological study on company employees in Westfalia. J Clin Chem Clin Biochem (1984) 1.04

Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol (1995) 1.03

A molecular model of high density lipoproteins. Proc Natl Acad Sci U S A (1974) 1.02

Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA-DR3. Scand J Rheumatol (2005) 1.02

Plasma lipoproteins and physical activity: a review. Int J Sports Med (1982) 1.02